search
Back to results

Efficacy and Safety Study of Elagolix Versus Placebo or Leuprorelin Acetate in Endometriosis

Primary Purpose

Endometriosis

Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Leuprorelin Acetate Depot
Elagolix
Placebo to Elagolix
Placebo to Leuprorelin Acetate
Sponsored by
AbbVie
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Endometriosis focused on measuring bone mineral density,endometriosis,pelvic pain

Eligibility Criteria

18 Years - 45 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria

  • Female, aged 18 to 45 years, inclusive
  • Have moderate to severe pelvic pain due to endometriosis
  • Have been surgically (laparoscopy) diagnosed with endometriosis within the last 5 years and have recurrent or persistent endometriosis symptoms
  • Have regular menstrual cycle (23-33 day)
  • Agree to use two forms of non-hormonal contraception during the study

Exclusion Criteria:

  • Received a Gonadotropin-releasing hormone (GnRH) agonist, GnRH antagonist, danazol, or have received any of these agents within 6 months of the start of screening.
  • Received subcutaneous medroxyprogesterone acetate (DMPA-SC) or intramuscular (i.m.) medroxyprogesterone acetate (DMPA-IM), or have received either of these agents within 3 months of the start of screening.
  • Are currently using hormonal contraception or other forms of hormonal therapy or received such treatment within the last month
  • Have had surgery for endometriosis within the last month
  • Are using systemic steroids on a chronic or regular basis within 3 months
  • Have uterine fibroids or other pelvic lesions ≥ 3 cm in diameter
  • Have had a hysterectomy or oophorectomy
  • Have pelvic pain that is not caused by endometriosis
  • Have unstable medical condition or chronic disease
  • Have been pregnant within the last 6 months and is currently breast feeding

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm 4

    Arm Type

    Placebo Comparator

    Experimental

    Experimental

    Other

    Arm Label

    Placebo

    Elagolix 150 mg

    Elagolix 250 mg

    Leuprorelin

    Arm Description

    Participants received placebo tablets once a day and placebo intramuscular injection once a month for 12 weeks. At the end of 12 weeks participants were re-randomized to receive one of the two doses of elagolix (150 mg or 250 mg) for 12 weeks.

    Participants received elagolix 150 mg tablets once a day and placebo intramuscular injection once a month for 12 weeks. At the end of 12 weeks participants continued to receive elagolix 150 mg for an additional 12 weeks.

    Participants received elagolix 250 mg tablets once a day and placebo intramuscular injection once a month for 12 weeks. At the end of 12 weeks participants continued to receive elagolix 250 mg for an additional 12 weeks.

    Participants received placebo tablets once a day and leuprorelin acetate 1-month depot 3.75 mg intramuscular injection once a month for 12 weeks. At the end of 12 weeks participants were re-randomized to receive one of the two doses of elagolix (150 mg or 250 mg) for 12 weeks.

    Outcomes

    Primary Outcome Measures

    Change From Baseline in the Monthly Mean Numerical Rating Score (NRS) for Endometriosis Pain
    The NRS is an 11-point scale used to measure endometriosis pain and was completed at approximately the same time each day using an electronic diary (e-Diary). Participants were instructed to select a single number between 0 (No pain) and 10 (Worst pain ever) that best described their endometriosis pain at its worst over the past day. The monthly mean NRS is the average of the daily values reported during the 4 weeks prior to each visit.

    Secondary Outcome Measures

    Change From Baseline in the Monthly Peak Numerical Rating Score (NRS) for Endometriosis Pain
    The NRS is an 11-point scale used to measure endometriosis pain and was completed at approximately the same time each day using an electronic diary (e-Diary). Participants were instructed to select a single number between 0 (No pain) and 10 (Worst pain ever) that best described their endometriosis pain at its worst over the past day. The monthly peak NRS is the maximum of the daily values reported during the 4 weeks prior to each visit.
    Change From Baseline in the Monthly Mean Non-menstrual Pelvic Pain Score
    Participants assessed their pelvic pain not related to menses and its impact on their daily activities at approximately the same time every day in an e-Diary according to the following response options: 0 = No pelvic pain 1 = Mild pelvic pain; subject could not do some of the things she usually does 2 = Moderate pelvic pain; subject could not do many of the things she usually does 3 = Severe pelvic pain; subject could not do most or all of the things she usually does. The monthly mean non-menstrual pelvic pain score is the average of the daily values reported during the 4 weeks prior to each visit.
    Change From Baseline in the Monthly Mean Dysmenorrhea Score
    Participants assessed dysmenorrhea (pain during menstruation) and its impact on their daily activities at approximately the same time each day of their period in an e-Diary according to the following response options: Subject is not having her period 0 = No pain related to period 1 = Mild pain related to period; subject could not do some of the things she usually does 2 = Moderate pain related to period; subject could not do many of the things she usually does 3 = Severe pain related to period; subject could not do most of or all of the things she usually does. The monthly mean dysmenorrhea score is the average of the daily values reported during the 4 weeks prior to each visit.
    Change From Baseline in the Monthly Mean Sum of Dysmenorrhea and Non-menstrual Pelvic Pain Scores
    Participants assessed dysmenorrhea and pelvic pain not related to menses and their impact on daily activities at approximately the same time every day on a 4-point scale (0 = none, 1 = mild, 2 = moderate, and 3 = severe) in an e-Diary. The dysmenorrhea scale included an option for participants who were not having their period. The sum of the dysmenorrhea and non-menstrual pelvic pain scores on each day were calculated to create a daily total score. On days the participant was not having her period, the dysmenorrhea score was not defined; hence, the total score was equal to the non-menstrual pelvic pain score (range 0 to 3). On days where the participant recorded menstruation the total score ranged from 0 to 6, where higher scores indicate more severe pain. The monthly mean sum of dysmenorrhea and non-menstrual pelvic pain scores is the average of the daily values reported during the 4 weeks prior to each visit.
    Change From Baseline in the Percentage of Days of Any Analgesic Use
    The daily use of endometriosis analgesics was reported by participants daily using the e-Diary. Participants reported whether the medication was over-the-counter (OTC) or prescription, and, if prescription, whether the medication was a narcotic. The percentage of days of any analgesic use is defined as the number of days in the 4 weeks prior to each study visit that the participant reported the use of an analgesic, divided by the number of study days in the interval that the participant provided an e-Diary report regarding the use of endometriosis analgesics (including a response of "none").
    Change From Baseline in the Percentage of Days of Prescription Analgesic Use
    The daily use of endometriosis analgesics was reported by participants daily using the e-Diary. Participants reported whether the medication was over-the-counter (OTC) or prescription, and, if prescription, whether the medication was a narcotic. The percentage of days of prescription analgesic use is defined as the number of days in the 4 weeks prior to each study visit that the participant reported the use of a prescription analgesic, divided by the number of study days in the interval that the participant provided an e-Diary report regarding the use of endometriosis analgesics (including a response of "none").
    Change From Baseline in the Percentage of Days of Narcotic Analgesic Use
    The daily use of endometriosis analgesics was reported by participants daily using the e-Diary. Participants reported whether the medication was over-the-counter (OTC) or prescription, and, if prescription, whether the medication was a narcotic. The percentage of days of narcotic analgesic use is defined as the number of days in the 4 weeks prior to each study visit that the participant reported the use of a narcotic analgesic, divided by the number of study days in the interval that the participant provided an e-Diary report regarding the use of endometriosis analgesics (including a response of "none").
    Change From Baseline in Dyspareunia Component of the Composite Pelvic Signs and Symptoms Score (CPSSS)
    The CPSSS consists of 5 components that address dysmenorrhea, dyspareunia, non-menstrual pelvic pain, pelvic tenderness, and pelvic induration. To assess dyspareunia (painful intercourse) participants were asked to select the best description of pain during sexual intercourse over the past 28 days using the following response categories: 0 = Absent; No discomfort during sexual intercourse. 1 = Mild; I can tolerate the discomfort during sexual intercourse. 2 = Moderate; Intercourse is sometime interrupted due to pain. 3 = Severe; I prefer to avoid intercourse because of pain. Not applicable. I am not sexually active for reasons other than my endometriosis symptoms.
    Change From Baseline in Dysmenorrhea Component of the CPSSS
    The CPSSS consists of 5 components that address dysmenorrhea, dyspareunia, non-menstrual pelvic pain, pelvic tenderness, and pelvic induration. To assess dysmenorrhea (pain during menstruation), participants were asked to select the best description of painful menstruation over the past 28 days using the following response categories: 0 = Absent; Amenorrhea (no bleeding) or no discomfort. 1 = Mild; Some loss of work efficiency; occasional use of analgesics. 2 = Moderate; In bed part of one day, occasional loss of work; regular use of analgesics. 3 = Severe; In bed ≥ 1 day, incapacitation; requirement for strong analgesics.
    Change From Baseline in Non-menstrual Pelvic Pain CPSSS Component
    The CPSSS consists of 5 components that address dysmenorrhea, dyspareunia, non-menstrual pelvic pain, pelvic tenderness, and pelvic induration. To assess non-menstrual pelvic pain, participants were asked to select the best description of pelvic pain over the past 28 days using the following response categories: 0 = Absent; No discomfort. 1 = Mild; Occasional pelvic discomfort that can be treated with NSAIDs. 2 = Moderate; Noticeable discomfort or pain for most of cycle requiring regular use of NSAID or weak opiate. 3 = Severe; Pain persisting during the cycle or pain requiring strong analgesics.
    Patient Global Impression of Change at Weeks 4, 8 and 12
    The Patient Global Impression of Change (PGIC) is a questionnaire-based assessment of the change in endometriosis pain since the initiation of study drug. The participant was asked to select from one of seven response categories: Very Much Improved Much Improved Minimally Improved Not Changed Minimally Worse Much Worse Very Much Worse
    Percentage of Participants With a PGIC Response of Minimally Improved, Much Improved, or Very Much Improved
    The PGIC is a questionnaire-based assessment of the change in endometriosis pain since the initiation of study drug. The participant was asked to select from one of seven response categories: Very Much Improved Much Improved Minimally Improved Not Changed Minimally Worse Much Worse Very Much Worse
    Percentage of Participants With a PGIC Response of Much Improved or Very Much Improved
    The PGIC is a questionnaire-based assessment of the change in endometriosis pain since the initiation of study drug. The participant was asked to select from one of seven response categories: Very Much Improved Much Improved Minimally Improved Not Changed Minimally Worse Much Worse Very Much Worse
    Change From Baseline in Endometriosis Health Profile-5 (EHP-5) at Week 12
    The EHP-5 is an instrument to measure health-related quality of life in women with endometriosis. The EHP-5 consists of two parts: A core questionnaire consisting of five questions that measure the areas of pain, control and powerlessness, emotional well-being, social support, and self-image with five response categories for each item (Never, Rarely, Sometimes, Often, Always) A supplemental questionnaire consisting of six additional questions which assess the areas of work, relationship with children, sexual intercourse, feelings about the medical profession, treatment, and infertility with the same five response categories plus an additional response category of Not Relevant which was not scored. The scores associated with each possible outcome category are as follows: never (0), rarely (25), sometimes (50), often (75), and always (100). A negative change from baseline score indicates improvement in quality of life.
    Concentration of Serum Estradiol
    The concentration of serum estradiol (E2) was quantified using liquid chromatography with tandem mass spectrophotometry (LC/MS/MS). Serum estradiol concentrations below the limit of quantification (BLQ) were set equal to the lower limit of quantification (2.5 pg/mL).
    Percent Change From Baseline in Bone Mineral Density of the Femur at Week 12
    Bone mineral density (BMD) of the femur (total hip) was measured by dual-energy X-ray absorptiometry (DXA).
    Percent Change From Baseline in Bone Mineral Density of the Spine at Week 12
    Bone mineral density (BMD) of the spine was measured by dual-energy X-ray absorptiometry (DXA).
    Percent Change From Baseline in Bone Mineral Density of the Femur at Week 24
    Bone mineral density (BMD) of the femur (total hip) was measured by dual-energy X-ray absorptiometry (DXA).
    Percent Change From Baseline in Bone Mineral Density of the Spine at Week 24
    Bone mineral density (BMD) of the spine was measured by dual-energy X-ray absorptiometry (DXA).
    Change From Baseline in Serum N-telopeptide Concentration at Week 12
    Blood samples to determine N-telopeptide concentrations were analyzed by a central laboratory using an enzyme-linked immunosorbent assay (ELISA).
    Average Number of Hot Flashes Per Day
    Hot flashes, if any, were reported daily by participants during the study using the e-Diary. The average number of hot flashes per day was calculated for each participant as the total number of hot flashes divided by total days in the phase.
    Percentage of Days With Uterine Bleeding
    Uterine bleeding was reported daily by participants during the study using the e-Diary. The percentage of days a participant reported any bleeding was calculated as the total number of days the participant reported any bleeding ( light, moderate, or heavy) divided by the total number of days the participant had a non-missing eDiary report of vaginal bleeding in the phase.
    Number of Days to First Posttreatment Menses
    Defined as the number of days from the last dose of study drug until the start date of the first post-treatment menses.

    Full Information

    First Posted
    November 21, 2008
    Last Updated
    August 9, 2018
    Sponsor
    AbbVie
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00797225
    Brief Title
    Efficacy and Safety Study of Elagolix Versus Placebo or Leuprorelin Acetate in Endometriosis
    Official Title
    A Phase II, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Assess the Efficacy and Safety of NBI-56418 in Subjects With Endometriosis
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    April 2018
    Overall Recruitment Status
    Completed
    Study Start Date
    November 26, 2008 (Actual)
    Primary Completion Date
    February 24, 2010 (Actual)
    Study Completion Date
    February 24, 2010 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    AbbVie

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    Yes
    Studies a U.S. FDA-regulated Device Product
    No
    Product Manufactured in and Exported from the U.S.
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    This study is designed to evaluate the safety and beneficial effects of elagolix (NBI-56418) compared to placebo and leuprorelin (an approved endometriosis therapy) over a three month period followed by an additional three months of treatment on elagolix.
    Detailed Description
    The study followed a parallel-group design in which participants were randomized (1:1:1:1) to one of the following treatment groups for the first 12 weeks of dosing: 150 mg elagolix once daily (q.d.); 250 mg elagolix q.d.; placebo; or leuprorelin acetate depot injection 3.75 mg (monthly). Blinding was achieved using a double-dummy design. Following 12 weeks of dosing, participants continued in the study for an additional 12 weeks; participants randomized to elagolix continued to receive their assigned dose and participants randomized to placebo or leuprorelin acetate were re-randomized to receive one of the two doses of elagolix (150 mg q.d. or 250 mg q.d.) for 12 weeks in a double-blind fashion. Six weeks after the last dose of the study drug at the end of Week 24, a follow-up visit was performed (end of Week 30). There was no pre-specified primary efficacy end point as there was no single key efficacy outcome measure in this exploratory Phase 2 study. For purposes of results reported here, Change From Baseline in the Monthly Mean Numerical Rating Score (NRS) for Endometriosis Pain is designated as the primary outcome measure.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Endometriosis
    Keywords
    bone mineral density,endometriosis,pelvic pain

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    174 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Placebo
    Arm Type
    Placebo Comparator
    Arm Description
    Participants received placebo tablets once a day and placebo intramuscular injection once a month for 12 weeks. At the end of 12 weeks participants were re-randomized to receive one of the two doses of elagolix (150 mg or 250 mg) for 12 weeks.
    Arm Title
    Elagolix 150 mg
    Arm Type
    Experimental
    Arm Description
    Participants received elagolix 150 mg tablets once a day and placebo intramuscular injection once a month for 12 weeks. At the end of 12 weeks participants continued to receive elagolix 150 mg for an additional 12 weeks.
    Arm Title
    Elagolix 250 mg
    Arm Type
    Experimental
    Arm Description
    Participants received elagolix 250 mg tablets once a day and placebo intramuscular injection once a month for 12 weeks. At the end of 12 weeks participants continued to receive elagolix 250 mg for an additional 12 weeks.
    Arm Title
    Leuprorelin
    Arm Type
    Other
    Arm Description
    Participants received placebo tablets once a day and leuprorelin acetate 1-month depot 3.75 mg intramuscular injection once a month for 12 weeks. At the end of 12 weeks participants were re-randomized to receive one of the two doses of elagolix (150 mg or 250 mg) for 12 weeks.
    Intervention Type
    Drug
    Intervention Name(s)
    Leuprorelin Acetate Depot
    Other Intervention Name(s)
    Prostap SR
    Intervention Description
    Leuprorelin acetate depot injection 3.75 mg administered as an intramuscular injection
    Intervention Type
    Drug
    Intervention Name(s)
    Elagolix
    Other Intervention Name(s)
    NBI-56418, Orilissa™
    Intervention Description
    Elagolix tablets administered orally
    Intervention Type
    Drug
    Intervention Name(s)
    Placebo to Elagolix
    Intervention Description
    Placebo tablet administered orally
    Intervention Type
    Drug
    Intervention Name(s)
    Placebo to Leuprorelin Acetate
    Intervention Description
    Saline solution administered as an intramuscular injection
    Primary Outcome Measure Information:
    Title
    Change From Baseline in the Monthly Mean Numerical Rating Score (NRS) for Endometriosis Pain
    Description
    The NRS is an 11-point scale used to measure endometriosis pain and was completed at approximately the same time each day using an electronic diary (e-Diary). Participants were instructed to select a single number between 0 (No pain) and 10 (Worst pain ever) that best described their endometriosis pain at its worst over the past day. The monthly mean NRS is the average of the daily values reported during the 4 weeks prior to each visit.
    Time Frame
    Baseline and Weeks 4, 8, and 12
    Secondary Outcome Measure Information:
    Title
    Change From Baseline in the Monthly Peak Numerical Rating Score (NRS) for Endometriosis Pain
    Description
    The NRS is an 11-point scale used to measure endometriosis pain and was completed at approximately the same time each day using an electronic diary (e-Diary). Participants were instructed to select a single number between 0 (No pain) and 10 (Worst pain ever) that best described their endometriosis pain at its worst over the past day. The monthly peak NRS is the maximum of the daily values reported during the 4 weeks prior to each visit.
    Time Frame
    Baseline and Weeks 4, 8, and 12
    Title
    Change From Baseline in the Monthly Mean Non-menstrual Pelvic Pain Score
    Description
    Participants assessed their pelvic pain not related to menses and its impact on their daily activities at approximately the same time every day in an e-Diary according to the following response options: 0 = No pelvic pain 1 = Mild pelvic pain; subject could not do some of the things she usually does 2 = Moderate pelvic pain; subject could not do many of the things she usually does 3 = Severe pelvic pain; subject could not do most or all of the things she usually does. The monthly mean non-menstrual pelvic pain score is the average of the daily values reported during the 4 weeks prior to each visit.
    Time Frame
    Baseline and Weeks 4, 8, and 12
    Title
    Change From Baseline in the Monthly Mean Dysmenorrhea Score
    Description
    Participants assessed dysmenorrhea (pain during menstruation) and its impact on their daily activities at approximately the same time each day of their period in an e-Diary according to the following response options: Subject is not having her period 0 = No pain related to period 1 = Mild pain related to period; subject could not do some of the things she usually does 2 = Moderate pain related to period; subject could not do many of the things she usually does 3 = Severe pain related to period; subject could not do most of or all of the things she usually does. The monthly mean dysmenorrhea score is the average of the daily values reported during the 4 weeks prior to each visit.
    Time Frame
    Baseline and Weeks 4, 8, and 12
    Title
    Change From Baseline in the Monthly Mean Sum of Dysmenorrhea and Non-menstrual Pelvic Pain Scores
    Description
    Participants assessed dysmenorrhea and pelvic pain not related to menses and their impact on daily activities at approximately the same time every day on a 4-point scale (0 = none, 1 = mild, 2 = moderate, and 3 = severe) in an e-Diary. The dysmenorrhea scale included an option for participants who were not having their period. The sum of the dysmenorrhea and non-menstrual pelvic pain scores on each day were calculated to create a daily total score. On days the participant was not having her period, the dysmenorrhea score was not defined; hence, the total score was equal to the non-menstrual pelvic pain score (range 0 to 3). On days where the participant recorded menstruation the total score ranged from 0 to 6, where higher scores indicate more severe pain. The monthly mean sum of dysmenorrhea and non-menstrual pelvic pain scores is the average of the daily values reported during the 4 weeks prior to each visit.
    Time Frame
    Baseline and Weeks 4, 8, and 12
    Title
    Change From Baseline in the Percentage of Days of Any Analgesic Use
    Description
    The daily use of endometriosis analgesics was reported by participants daily using the e-Diary. Participants reported whether the medication was over-the-counter (OTC) or prescription, and, if prescription, whether the medication was a narcotic. The percentage of days of any analgesic use is defined as the number of days in the 4 weeks prior to each study visit that the participant reported the use of an analgesic, divided by the number of study days in the interval that the participant provided an e-Diary report regarding the use of endometriosis analgesics (including a response of "none").
    Time Frame
    Baseline, Weeks 4, 8 and 12
    Title
    Change From Baseline in the Percentage of Days of Prescription Analgesic Use
    Description
    The daily use of endometriosis analgesics was reported by participants daily using the e-Diary. Participants reported whether the medication was over-the-counter (OTC) or prescription, and, if prescription, whether the medication was a narcotic. The percentage of days of prescription analgesic use is defined as the number of days in the 4 weeks prior to each study visit that the participant reported the use of a prescription analgesic, divided by the number of study days in the interval that the participant provided an e-Diary report regarding the use of endometriosis analgesics (including a response of "none").
    Time Frame
    Baseline, Weeks 4, 8 and 12
    Title
    Change From Baseline in the Percentage of Days of Narcotic Analgesic Use
    Description
    The daily use of endometriosis analgesics was reported by participants daily using the e-Diary. Participants reported whether the medication was over-the-counter (OTC) or prescription, and, if prescription, whether the medication was a narcotic. The percentage of days of narcotic analgesic use is defined as the number of days in the 4 weeks prior to each study visit that the participant reported the use of a narcotic analgesic, divided by the number of study days in the interval that the participant provided an e-Diary report regarding the use of endometriosis analgesics (including a response of "none").
    Time Frame
    Baseline, Weeks 4, 8 and 12
    Title
    Change From Baseline in Dyspareunia Component of the Composite Pelvic Signs and Symptoms Score (CPSSS)
    Description
    The CPSSS consists of 5 components that address dysmenorrhea, dyspareunia, non-menstrual pelvic pain, pelvic tenderness, and pelvic induration. To assess dyspareunia (painful intercourse) participants were asked to select the best description of pain during sexual intercourse over the past 28 days using the following response categories: 0 = Absent; No discomfort during sexual intercourse. 1 = Mild; I can tolerate the discomfort during sexual intercourse. 2 = Moderate; Intercourse is sometime interrupted due to pain. 3 = Severe; I prefer to avoid intercourse because of pain. Not applicable. I am not sexually active for reasons other than my endometriosis symptoms.
    Time Frame
    Baseline and Weeks 4, 8, and 12
    Title
    Change From Baseline in Dysmenorrhea Component of the CPSSS
    Description
    The CPSSS consists of 5 components that address dysmenorrhea, dyspareunia, non-menstrual pelvic pain, pelvic tenderness, and pelvic induration. To assess dysmenorrhea (pain during menstruation), participants were asked to select the best description of painful menstruation over the past 28 days using the following response categories: 0 = Absent; Amenorrhea (no bleeding) or no discomfort. 1 = Mild; Some loss of work efficiency; occasional use of analgesics. 2 = Moderate; In bed part of one day, occasional loss of work; regular use of analgesics. 3 = Severe; In bed ≥ 1 day, incapacitation; requirement for strong analgesics.
    Time Frame
    Baseline and Week 12
    Title
    Change From Baseline in Non-menstrual Pelvic Pain CPSSS Component
    Description
    The CPSSS consists of 5 components that address dysmenorrhea, dyspareunia, non-menstrual pelvic pain, pelvic tenderness, and pelvic induration. To assess non-menstrual pelvic pain, participants were asked to select the best description of pelvic pain over the past 28 days using the following response categories: 0 = Absent; No discomfort. 1 = Mild; Occasional pelvic discomfort that can be treated with NSAIDs. 2 = Moderate; Noticeable discomfort or pain for most of cycle requiring regular use of NSAID or weak opiate. 3 = Severe; Pain persisting during the cycle or pain requiring strong analgesics.
    Time Frame
    Baseline and Week 12
    Title
    Patient Global Impression of Change at Weeks 4, 8 and 12
    Description
    The Patient Global Impression of Change (PGIC) is a questionnaire-based assessment of the change in endometriosis pain since the initiation of study drug. The participant was asked to select from one of seven response categories: Very Much Improved Much Improved Minimally Improved Not Changed Minimally Worse Much Worse Very Much Worse
    Time Frame
    Weeks 4, 8 and 12
    Title
    Percentage of Participants With a PGIC Response of Minimally Improved, Much Improved, or Very Much Improved
    Description
    The PGIC is a questionnaire-based assessment of the change in endometriosis pain since the initiation of study drug. The participant was asked to select from one of seven response categories: Very Much Improved Much Improved Minimally Improved Not Changed Minimally Worse Much Worse Very Much Worse
    Time Frame
    Weeks 4, 8 and 12
    Title
    Percentage of Participants With a PGIC Response of Much Improved or Very Much Improved
    Description
    The PGIC is a questionnaire-based assessment of the change in endometriosis pain since the initiation of study drug. The participant was asked to select from one of seven response categories: Very Much Improved Much Improved Minimally Improved Not Changed Minimally Worse Much Worse Very Much Worse
    Time Frame
    Weeks 4, 8 and 12
    Title
    Change From Baseline in Endometriosis Health Profile-5 (EHP-5) at Week 12
    Description
    The EHP-5 is an instrument to measure health-related quality of life in women with endometriosis. The EHP-5 consists of two parts: A core questionnaire consisting of five questions that measure the areas of pain, control and powerlessness, emotional well-being, social support, and self-image with five response categories for each item (Never, Rarely, Sometimes, Often, Always) A supplemental questionnaire consisting of six additional questions which assess the areas of work, relationship with children, sexual intercourse, feelings about the medical profession, treatment, and infertility with the same five response categories plus an additional response category of Not Relevant which was not scored. The scores associated with each possible outcome category are as follows: never (0), rarely (25), sometimes (50), often (75), and always (100). A negative change from baseline score indicates improvement in quality of life.
    Time Frame
    Baseline and week 12
    Title
    Concentration of Serum Estradiol
    Description
    The concentration of serum estradiol (E2) was quantified using liquid chromatography with tandem mass spectrophotometry (LC/MS/MS). Serum estradiol concentrations below the limit of quantification (BLQ) were set equal to the lower limit of quantification (2.5 pg/mL).
    Time Frame
    Baseline and Weeks 4, 8 and 12
    Title
    Percent Change From Baseline in Bone Mineral Density of the Femur at Week 12
    Description
    Bone mineral density (BMD) of the femur (total hip) was measured by dual-energy X-ray absorptiometry (DXA).
    Time Frame
    Baseline and week 12
    Title
    Percent Change From Baseline in Bone Mineral Density of the Spine at Week 12
    Description
    Bone mineral density (BMD) of the spine was measured by dual-energy X-ray absorptiometry (DXA).
    Time Frame
    Baseline and week 12
    Title
    Percent Change From Baseline in Bone Mineral Density of the Femur at Week 24
    Description
    Bone mineral density (BMD) of the femur (total hip) was measured by dual-energy X-ray absorptiometry (DXA).
    Time Frame
    Baseline and Week 24
    Title
    Percent Change From Baseline in Bone Mineral Density of the Spine at Week 24
    Description
    Bone mineral density (BMD) of the spine was measured by dual-energy X-ray absorptiometry (DXA).
    Time Frame
    Baseline and Week 24
    Title
    Change From Baseline in Serum N-telopeptide Concentration at Week 12
    Description
    Blood samples to determine N-telopeptide concentrations were analyzed by a central laboratory using an enzyme-linked immunosorbent assay (ELISA).
    Time Frame
    Baseline and week 12
    Title
    Average Number of Hot Flashes Per Day
    Description
    Hot flashes, if any, were reported daily by participants during the study using the e-Diary. The average number of hot flashes per day was calculated for each participant as the total number of hot flashes divided by total days in the phase.
    Time Frame
    Screening (8 weeks prior to day 1), Treatment phase (weeks 1 to 12 for participants in the placebo and leuprorelin treatment groups and weeks 1 to 24 for participants in the elagolix treatment groups)
    Title
    Percentage of Days With Uterine Bleeding
    Description
    Uterine bleeding was reported daily by participants during the study using the e-Diary. The percentage of days a participant reported any bleeding was calculated as the total number of days the participant reported any bleeding ( light, moderate, or heavy) divided by the total number of days the participant had a non-missing eDiary report of vaginal bleeding in the phase.
    Time Frame
    Screening (8 weeks prior to day 1), Treatment phase (weeks 1 to 12 for participants in the placebo and leuprorelin treatment groups and weeks 1 to 24 for participants in the elagolix treatment groups)
    Title
    Number of Days to First Posttreatment Menses
    Description
    Defined as the number of days from the last dose of study drug until the start date of the first post-treatment menses.
    Time Frame
    From last day of study drug up to 6 weeks after the last dose.

    10. Eligibility

    Sex
    Female
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    45 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria Female, aged 18 to 45 years, inclusive Have moderate to severe pelvic pain due to endometriosis Have been surgically (laparoscopy) diagnosed with endometriosis within the last 5 years and have recurrent or persistent endometriosis symptoms Have regular menstrual cycle (23-33 day) Agree to use two forms of non-hormonal contraception during the study Exclusion Criteria: Received a Gonadotropin-releasing hormone (GnRH) agonist, GnRH antagonist, danazol, or have received any of these agents within 6 months of the start of screening. Received subcutaneous medroxyprogesterone acetate (DMPA-SC) or intramuscular (i.m.) medroxyprogesterone acetate (DMPA-IM), or have received either of these agents within 3 months of the start of screening. Are currently using hormonal contraception or other forms of hormonal therapy or received such treatment within the last month Have had surgery for endometriosis within the last month Are using systemic steroids on a chronic or regular basis within 3 months Have uterine fibroids or other pelvic lesions ≥ 3 cm in diameter Have had a hysterectomy or oophorectomy Have pelvic pain that is not caused by endometriosis Have unstable medical condition or chronic disease Have been pregnant within the last 6 months and is currently breast feeding
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    AbbVie Inc.
    Organizational Affiliation
    AbbVie
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Plan to Share IPD
    Undecided

    Learn more about this trial

    Efficacy and Safety Study of Elagolix Versus Placebo or Leuprorelin Acetate in Endometriosis

    We'll reach out to this number within 24 hrs